HPV初筛与细胞学筛查对48个月高级别宫颈上皮内瘤变影响的随机临床试验
结果显示HPV组CIN3+发生率为2.3/1000,细胞学组为5.5/1000,风险比0.42(95%CI 0.25-0.69),HPV初筛显著降低CIN3+风险。
要点
- HPV初筛组48个月CIN3+发生率2.3/1000,显著低于细胞学组的5.5/1000,风险比0.42。
- HPV初筛组CIN2+发生率5.0/1000,也显著低于细胞学组的10.6/1000,风险比0.47。
- 基线HPV阴性女性CIN3+累积发生率1.4/1000,显著低于细胞学阴性女性,风险比0.25。
核心结论
- 在宫颈癌筛查女性中,与细胞学筛查相比,HPV初筛使48个月时CIN3+的检出风险显著降低。
- 需进一步研究长期临床结局和成本效益。
研究设计与样本
- 随机临床试验在加拿大有组织的宫颈癌筛查项目中进行,2008年1月至2012年5月通过224名合作临床医生招募,随访至2016年12月。
- 干预组HPV阴性者48个月返回;对照组细胞学阴性者24个月返回复查液基细胞学,24个月阴性者48个月返回;48个月时两组均接受HPV和液基细胞学联合检测。
- 主要结局为随机化后48个月CIN3+的累积发生率,次要结局为CIN2+累积发生率。
主要发现
- 48个月时干预组CIN3+发生率为2.3/1000(95%CI 1.5-3.5),对照组为5.5/1000(95%CI 4.2-7.2),CIN3+风险比0.42(95%CI 0.25-0.69)。
- 48个月时干预组CIN2+发生率为5.0/1000(95%CI 3.8-6.7),对照组为10.6/1000(95%CI 8.7-12.9),CIN2+风险比0.47(95%CI 0.34-0.67)。
- 基线HPV阴性女性48个月CIN3+累积发生率为1.4/1000(95%CI 0.8-2.4),CIN3+风险比0.25(95%CI 0.13-0.48),显著低于细胞学阴性女性。
临床怎么用
- 在宫颈癌筛查中可考虑采用HPV初筛替代细胞学筛查,以降低48个月时CIN3+的检出风险。
- HPV初筛阴性女性的CIN3+累积风险显著低于细胞学阴性女性,支持延长筛查间隔。
局限性
- 长期临床结局(如宫颈癌发病率和死亡率)尚未报告,需进一步研究。
- 成本效益需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is limited information about the relative effectiveness of cervical cancer screening with primary human papillomavirus (HPV) testing alone compared with cytology in North American populations. OBJECTIVE: To evaluate histologically confirmed cumulative incident cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+) detected up to and including 48 months by primary HPV testing alone (intervention) or liquid-based cytology (control). DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted in an organized Cervical Cancer Screening Program in Canada. Participants were recruited through 224 collaborating clinicians from January 2008 to May 2012, with follow-up through December 2016. Women aged 25 to 65 years with no history of CIN2+ in the past 5 years, no history of invasive cervical cancer, or no history of hysterectomy; who have not received a Papanicolaou test within the past 12 months; and who were not receiving immunosuppressive therapy were eligible. INTERVENTIONS: A total of 19 009 women were randomized to the intervention (n = 9552) and control (n = 9457) groups. Women in the intervention group received HPV testing; those whose results were negative returned at 48 months. Women in the control group received liquid-based cytology (LBC) testing; those whose results were negative returned at 24 months for LBC. Women in the control group who were negative at 24 months returned at 48 months. At 48-month exit, both groups received HPV and LBC co-testing. MAIN OUTCOMES AND MEASURES: The primary outcome was the cumulative incidence of CIN3+ 48 months following randomization. The cumulative incidence of CIN2+ was a secondary outcome. RESULTS: Among 19 009 women who were randomized (mean age, 45 years [10th-90th percentile, 30-59]), 16 374 (8296 [86.9%] in the intervention group and 8078 [85.4%] in the control group) completed the study. At 48 months, significantly fewer CIN3+ and CIN2+ were detected in the intervention vs control group. The CIN3+ incidence rate was 2.3/1000 (95% CI, 1.5-3.5) in the intervention group and 5.5/1000 (95% CI, 4.2-7.2) in the control group. The CIN3+ risk ratio was 0.42 (95% CI, 0.25-0.69). The CIN2+ incidence rate at 48 months was 5.0/1000 (95% CI, 3.8-6.7) in the intervention group and 10.6/1000 (95% CI, 8.7-12.9) in the control group. The CIN2+ risk ratio was 0.47 (95% CI, 0.34-0.67). Baseline HPV-negative women had a significantly lower cumulative incidence of CIN3+ at 48 months than cytology-negative women (CIN3+ incidence rate, 1.4/1000 [95% CI, 0.8-2.4]; CIN3+ risk ratio, 0.25 [95% CI, 0.13-0.48]). CONCLUSIONS AND RELEVANCE: Among women undergoing cervical cancer screening, the use of primary HPV testing compared with cytology testing resulted in a significantly lower likelihood of CIN3+ at 48 months. Further research is needed to understand long-term clinical outcomes as well as cost-effectiveness. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN79347302.
引用
- Ogilvie GS, van Niekerk D, Krajden M, et al. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial. JAMA. 2018. PMID: 29971397. doi:10.1001/jama.2018.7464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。